Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Open Hepatectomy

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1/2 (1)

Trial Status

Completed2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06342414Recruiting

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

NCT03397654Phase 1/2CompletedPrimary

Study of Pembrolizumab Following TACE in Primary Liver Carcinoma

NCT02014025Not ApplicableCompletedPrimary

Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC

Showing all 3 trials

Research Network

Common Treatments

  • Open Hepatectomy1
  • Elucidate1
  • Transarterial Chemoembolization1
  • Laparoscope Hepatectomy1
  • Pembrolizumab1

Active Sponsors

  • City of Hope Medical Center1
  • Shuguo Zheng, MD1
  • Merck Sharp & Dohme LLC1
  • Imperial College London1

Top Investigators

  • Ajay Goel, PhD1

    City of Hope Medical Center

  • Shuguo Zheng1

    Shuguo Zheng, MD Study Director Institute of Hepatobiliary Surgery ,Southwest Hospital ,Third Military Medical University

Related Conditions

  • Hepatic Cancer1
  • Primary Liver Cancer1
  • Hepatocellular Carcinoma1
  • Intrahepatic Cholangiocarcinoma1
  • Hepatic Carcinoma1

Activity Timeline